Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The investigators seek to determine whether adjunctive topical fluorometholone (FML) improves best-corrected visual acuity (BCVA) at 3 months in patients with bacterial corneal ulcers compared with standard topical antibiotic therapy alone.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- NOT_YET_RECRUITING
- phase
- PHASE2
- study type
- INTERVENTIONAL
- enrollment
- 174
- sponsor
- Vishal Jhanji
- conditions
- Keratitis Bacterial; Corneal Ulcer (Diagnosis)
- interventions
- DRUG: Adjunctive Topical Fluorometholone (FML) 0.1%; DRUG: Standard Topical Antibiotic Therapy
- start date
- 2026-10-31
- start date type
- ESTIMATED
- primary completion date
- 2029-12-31
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT07308938
- Published
- Dec 30, 2025
- Updated
- Jun 10, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT07308938
- Categories
- Keratitis Bacterial, Corneal Ulcer (Diagnosis)
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials